Threshold Pharma (THLD) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-20.41M
Depreciation and amortization
Stock-based compensation expense	2.44M
Change in common stock warrant value
Amortization of debt issuance costs
Loss on sale of investments, property and equipment
Prepaid expenses and other assets	1.74M
Accounts payable	-26K
Accrued clinical and development expenses
Accrued liabilities	-2.16M
Deferred rent
Net cash used in operating activities
Acquisition of property and equipment	0
Acquisition of marketable securities
Proceeds from sales and maturities of marketable securities
Restricted cash
Net cash provided by (used in) investing activities
Proceeds from redeemable convertible preferred stock, net
Proceeds from issuance of common stock and warrants, net of offering expenses	27K
Deferred offering costs
Proceeds from issuance of notes payable
Repayment of notes payable
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents	5.57M
Cash and cash equivalents, beginning of period	9.59M
Cash and cash equivalents, end of period	15.16M
Deferred stock-based compensation
Cumulative effect of change in accounting principle - Reclassification of common stock warrants to liability upon adoption of ASC 815
Change in unrealized gain (loss) on marketable securities
Conversion of redeemable preferred stock
Dividend related to beneficial conversion feature of redeemable convertible preferred stock.

Entities mentioned with THLD

View All Entities